Guggenheim Analyst is Bullish on Guardant Health, Inc. (GH)

Guardant Health, Inc. (NASDAQ:GH) is among the 20 Best Performing Stocks in 2025.

On January 5, 2026, TheFly reported that Wall Street firms had given Guardant Health, Inc. (NASDAQ:GH) two price target raises. Subbu Nambi, an analyst at Guggenheim, increased the firm’s price objective for the corporation from $85 to $115 and retained a buy rating. Guggenheim stated that in response to recent updates given during discussions with management teams, it modified models and projections for covered Diagnostics and Life Sciences Tools companies.

Separately, on December 22, 2025, Canaccord maintained its Buy recommendation on Guardant Health, Inc. (NASDAQ:GH) shares and raised its price objective from $100 to $125. Canaccord stated that it expects the sector momentum that started in the second part of the year to be sustained in 2026 and gave an overview of its coverage of life science tools and diagnostics. Canaccord claimed to have the strongest confidence in the company’s risk-reward profile and potential for share price growth among the firms covered.

Guardant Health, Inc. (NASDAQ:GH) is a leader in liquid-based cancer testing for clinical and research applications.

While we acknowledge the potential of GH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None